Table 3.
Comparisons of Larger (>10 cm) (n = 59) vs. Smaller (≤10 cm) Tumors (n = 29)
| Parameter | Tumor group | Sig. | |||
|---|---|---|---|---|---|
| Smaller | Larger | ||||
| Categorical | N | % | N | % | |
| Presence of ascites | 12 | 41.4 | 47 | 79.7 | <0.001 |
| Lateralitya | 1.00 | ||||
| Right | 17 | 58.6 | 36 | 61 | |
| Left | 11 | 37.9 | 22 | 37.3 | |
| Bilateral | 1 | 3.4 | 1 | 1.7 | |
| Cystic changes | 14 | 48.3 | 43 | 72.9 | 0.023 |
| Borderb | 0.004 | ||||
| Regular smooth | 29 | 100 | 46 | 78 | |
| Lobulated | 0 | 0 | 13 | 22 | |
| Echogenicity (US)a | 0.003 | ||||
| Hypoechoic | 21 | 72.4 | 20 | 35.1 | |
| Isoechoic | 7 | 24.1 | 25 | 43.9 | |
| Mixed hyperechoic | 1 | 3.4 | 12 | 21.1 | |
| Vascularity (US)a | 0.461 | ||||
| No | 11 | 37.9 | 14 | 23.7 | |
| Mild | 17 | 58.6 | 42 | 71.2 | |
| Moderate | 1 | 3.4 | 2 | 3.4 | |
| Marked | 0 | 0 | 1 | 1.7 | |
| MRI T2 signal intensitya (n = 37) | 0.074 | ||||
| Hypointense | 5 | 35.7 | 5 | 21.7 | |
| Intermediate/isointense | 9 | 64.3 | 11 | 47.8 | |
| Mixed hyperintense | 0 | 0 | 7 | 30.4 | |
| MRI postcontrast enhancementa (n = 37) | 0.620 | ||||
| Mild | 13 | 92.9 | 22 | 95.7 | |
| Moderate | 1 | 7.1 | 0 | 0 | |
| Marked | 0 | 0 | 1 | 4.3 | |
| DWI signal intensitya (n = 37) | 0.043 | ||||
| Low | 6 | 42.9 | 2 | 8.7 | |
| Intermediate | 8 | 57.1 | 19 | 82.6 | |
| High | 0 | 0 | 2 | 8.7 | |
| CT enhancementa | 0.207 | ||||
| No | 12 | 41.4 | 15 | 25.4 | |
| Mild | 17 | 58.6 | 43 | 72.9 | |
| Moderate | 0 | 0 | 1 | 1.7 | |
| Clinical presentation | |||||
| Abdominal enlargementb | 0 | 0 | 6 | 10.2 | 0.172 |
| Abnormal uterine bleedingb | 1 | 3.4 | 0 | 0 | 0.330 |
| Asymptomaticb | 3 | 10.3 | 0 | 0 | 0.033 |
| Pelvic-abdominal painb | 25 | 86.2 | 54 | 91.5 | 0.469 |
| Abdominal | 8 | 32 | 11 | 20.4 | 0.272 |
| Pelvic | 17 | 68 | 43 | 79.6 | |
| Surgical technique | 0.039 | ||||
| Open | 25 | 86.2 | 58 | 98.3 | |
| Laparoscopic | 4 | 13.8 | 1 | 1.7 | |
| Surgery type | 0.075 | ||||
| Salpingo-oophorectomy | 21 | 72.4 | 31 | 52.5 | |
| TAH/BSO | 8 | 27.6 | 28 | 47.5 | |
| Associated endometrial hyperplasiab | 2 | 6.9 | 8 | 13.6 | 0.487 |
| Associated uterine leiomyomab | 0 | 0 | 2 | 3.4 | 1.00 |
| Associated adenomyosisb | 0 | 0 | 4 | 6.8 | 0.298 |
| Associated atrophic endometriumb | 1 | 3.4 | 1 | 1.7 | 1.00 |
| Numerical | Median | Q1–Q3 | Median | Q1–Q3 | Sig. |
|---|---|---|---|---|---|
| Age (years) | 55 | 46–60.5 | 55 | 50–62 | 0.631 |
| CA 125 | 25 | 12.8–89.5 | 129.4 | 56.3–313 | <0.001 |
| CA 19-9 | 7.63 | 3.25–9.63 | 10.4 | 4.3–23.8 | 0.187 |
| CEA | 1 | 1–1.6 | 1.6 | 1–2.4 | 0.184 |
Bold values indicate significant p values.
Q1–Q3, 25th–75th percentiles; Sig., significance (p-value). The tests of significance for categorical data are chi-square test, Fisher’s exact test, and Fisher-Freeman-Halton exact test. The test of significance for numerical data is Mann-Whitney U test.
aFisher-Freeman-Halton exact test.
bFisher’s exact test.